Cardiology Research and Practice / 2019 / Article / Tab 1

Research Article

Resting Heart Rate and Long-Term Outcomes in Patients with Percutaneous Coronary Intervention: Results from a 10-Year Follow-Up of the CORFCHD-PCI Study

Table 1

Baseline characteristics of patients.

VariablesHeart rate before PCIF or X2 value
<66 beats/min66–72 beats/min72–78 beats/min78–84 beats/min≥84 beats/min

Total population
Female, (%)281 (25.0)256 (25.3)354 (24.5)329 (27.2)331 (26.2)2.8660.581
Smoking, (%)429 (38.2)427 (42.3)601 (41.7)482 (39.8)482 (38.2)7.1810.127
Drinking, (%)309 (27.5)305 (30.2)433 (30.0)349 (28.8)371 (29.4)2.6080.625
Diabetes, (%)217 (19.3)196 (19.4)362 (25.1)308 (25.4)368 (29.1)45.769<0.001
Hypertension, (%)440 (39.2)404 (40.0)594 (41.2)520 (42.9)598 (47.3)20.778<0.001
Age (years)60.98 ± 10.7759.77 ± 10.9359.08 ± 10.7459.43 ± 10.6958.49 ± 10.928.723<0.001
BMI (kg/m2)25.55 ± 4.0425.71 ± 6.8925.73 ± 4.2826.2 ± 10.2526.57 ± 8.611.6540.158
SBP (mmHg)125.1 ± 19.15125.23 ± 18.18125.9 ± 17.14128.52 ± 18.46130.06 ± 20.4416.904<0.001
DBP (mmHg)74.2 ± 11.2774.92 ± 10.6375.62 ± 10.3277.05 ± 11.2379.37 ± 12.2840.36<0.001
HR (beats/min)60.5 ± 3.8568.77 ± 1.5574.31 ± 1.7179.79 ± 1.4791.81 ± 8.139115.745<0.001
TG (mmol/L)1.89 ± 1.261.85 ± 1.151.9 ± 1.271.91 ± 1.331.93 ± 1.310.6120.654
TC (mmol/L)3.95 ± 1.113.95 ± 1.063.94 ± 1.093.95 ± 1.114.01 ± 1.160.7460.561
HDL-C (mmol/L)1.0 ± 0.371.0 ± 0.411.02 ± 0.491.02 ± 0.471.05 ± 0.621.8090.124
LDL-C (mmol/L)2.43 ± 0.892.46 ± 0.92.45 ± 0.922.46 ± 0.92.5 ± 0.971.0690.37
ApoA1 (mmol/L)1.17 ± 0.311.16 ± 0.311.16 ± 0.311.16 ± 0.331.17 ± 0.320.2020.938
ApoB (mmol/L)0.85 ± 0.370.86 ± 0.450.85 ± 0.430.86 ± 0.420.85 ± 0.310.150.963
Lp(a) (mmol/L)219.53 ± 178.71222.2 ± 177.77217.78 ± 170.99216.14 ± 178.61226.1 ± 178.940.580.677
New generation stent, (%)1060 (94.4)951 (94.3)1355 (94.0)1134 (93.6)1199 (94.9)2.1560.707
CTO, (%)211 (18.8)194 (19.2)302 (20.9)326 (26.9)381 (30.2)68.650<0.001
LM, (%)84 (7.5)79 (7.8)92 (6.4)92 (7.6)86 (6.8)2.7550.600
ML, (%)705 (62.8)632 (62.6)926 (64.2)822 (67.9)841 (66.6)11.0790.026
CCB, (%)132 (11.8)114 (11.4)190 (13.2)126 (10.5)129 (10.3)7.5920.108
β-Blockers, (%)446 (39.9)402 (40.1)589 (41.0)525 (43.6)466 (37.0)11.2740.024
ARB or ACEI, (%)232 (20.8)235 (23.5)320 (22.3)284 (23.6)296 (23.5)3.9490.413
Clopidogrel, (%)325 (29.1)312 (31.3)470 (32.8)369 (30.7)361 (28.8)6.6440.156
Aspirin, (%)769 (69.0)725 (72.6)963 (67.0)801 (66.5)793 (63.1)24.313<0.001
Statins, (%)600 (53.9)565 (56.7)797 (55.8)656 (54.6)641 (51.0)9.2050.056
LVEDD (mm)50.13 ± 5.8249.99 ± 5.5849.77 ± 5.5850.08 ± 5.4249.97 ± 5.280.7070.587
LVEF (%)60.94 ± 7.1861.09 ± 7.0061.29 ± 6.8961.15 ± 7.0960.85 ± 7.060.6870.601

ACS patients
Female, (%)121 (24.9)109 (24.5)158 (27.5)33 (29.5)110 (25.7)2.1780.703
Smoking, (%)187 (38.6)199 (44.8)235 (40.9)44 (39.3)177 (41.4)3.9890.407
Drinking, (%)134 (27.6)138 (31.1)162 (28.2)39 (34.8)131 (30.6)3.5690.467
Diabetes, (%)98 (20.2)77 (17.3)147 (25.6)33 (29.5)125 (29.2)23.683<0.001
Hypertension, (%)188 (38.8)173 (39.0)251 (43.7)57 (50.9)202 (47.2)12.4640.014
Age (years)61.01 ± 10.7559.91 ± 10.9559.76 ± 10.7260.66 ± 10.7458.51 ± 11.403.1490.014
SBP (mmHg)125.09 ± 19.69126.09 ± 17.33126.19 ± 17.03129.14 ± 16.40129.34 ± 21.853.6970.005
DBP (mmHg)73.85 ± 10.9975.49 ± 10.5675.72 ± 10.0175.10 ± 8.9880.15 ± 13.0420.280<0.001
HR (beats/min)60.47 ± 3.9868.81 ± 1.5774.35 ± 1.6978.00 ± 0.0095.84 ± 8.693659.925<0.001
TG (mmol/L)1.87 ± 1.321.84 ± 1.151.93 ± 1.311.94 ± 1.312.04 ± 1.381.3670.240
TC (mmol/L)3.99 ± 1.133.89 ± 1.053.95 ± 1.063.91 ± 1.004.01 ± 1.110.8300.506
HDL-C (mmol/L)1.04 ± 0.441.01 ± 0.421.02 ± 0.431.01 ± 0.471.03 ± 0.460.0750.990
LDL-C (mmol/L)2.45 ± 0.912.38 ± 0.852.44 ± 0.892.51 ± 0.982.46 ± 0.930.6260.644
ApoA1 (mmol/L)1.17 ± 0.361.17 ± 0.311.16 ± 0.301.19 ± 0.521.18 ± 0.350.2380.917
ApoB (mmol/L)0.86 ± 0.450.86 ± 0.530.85 ± 0.440.85 ± 0.350.85 ± 0.310.1410.967
Lp(a) (mmol/L)227.91 ± 189.34216.69 ± 156.76213.64 ± 165.52225.85 ± 164.24223.11 ± 166.600.5330.712
New generation stent, (%)461 (95.1)418 (94.4)544 (94.8)104 (92.9)409 (95.6)1.6020.808
CTO, (%)98 (20.2)87 (19.6)105 (18.3)25 (22.3)177 (41.4)89.298<0.001
LM, (%)44 (9.1)40 (9.0)46 (8.0)13 (11.6)39 (9.1)1.6160.806
ML, (%)341 (70.3)283 (63.9)384 (66.9)87 (77.7)315 (73.6)15.1820.004
CCB, (%)61 (12.7)60 (13.6)80 (14.0)8 (7.1)43 (10.1)6.9940.136
β-Blockers, (%)200 (41.4)178 (40.5)241 (42.2)47 (42.0)156 (36.5)3.7410.442
ARB or ACEI, (%)99 (20.5)101 (23.0)126 (22.1)24 (21.4)118 (27.6)7.2300.124
Clopidogrel, (%)151 (31.4)138 (31.5)183 (32.1)35 (31.3)148 (34.7)1.5340.821
Aspirin, (%)324 (67.5)322 (73.5)390 (68.3)78 (69.6)281 (66.0)6.6190.157
Statins, (%)262 (54.6)245 (56.1)331 (58.3)60 (53.6)210 (49.4)8.1090.088
LVEDD (mm)50.32 ± 5.5049.82 ± 5.4849.84 ± 5.5549.82 ± 4.1049.98 ± 5.630.6010.662
LVEF (%)61.02 ± 7.0961.25 ± 6.7160.98 ± 6.8462.31 ± 5.6160.58 ± 7.251.3450.251

Stable CAD patients
Female, (%)160 (25.1)147 (26.0)196 (22.6)296 (26.9)221 (26.5)5.6220.229
Smoking, (%)242 (37.9)228 (40.3)366 (42.2)438 (39.9)305 (36.5)6.5230.163
Drinking, (%)175 (27.4)167 (29.5)271 (31.2)310 (28.2)240 (28.7)3.2720.513
Diabetes, (%)119 (18.7)119 (21.0)215 (24.8)275 (25.0)243 (29.1)25.282<0.001
Hypertension, (%)252 (39.5)231 (40.8)343 (39.5)463 (42.1)396 (47.4)14.2490.007
Age (years)60.95 ± 10.8059.65 ± 10.9358.63 ± 10.7559.31 ± 10.6858.48 ± 10.675.973<0.001
SBP (mmHg)125.10 ± 18.74124.55 ± 18.80125.70 ± 17.22128.46 ± 18.66130.42 ± 19.6813.794<0.001
DBP (mmHg)74.47 ± 11.4874.48 ± 10.6775.55 ± 10.5277.24 ± 11.4278.97 ± 11.8622.586<0.001
HR (beats/min)60.53 ± 3.7568.74 ± 1.5474.28 ± 1.7279.97 ± 1.4289.74 ± 6.976480.176<0.001
TG (mmol/L)1.90 ± 1.201.86 ± 1.151.88 ± 1.241.91 ± 1.341.88 ± 1.270.1900.994
TC (mmol/L)3.92 ± 1.103.99 ± 1.073.94 ± 1.113.96 ± 1.124.01 ± 1.190.7520.557
HDL-C (mmol/L)1.00 ± 0.301.00 ± 0.391.03 ± 0.521.02 ± 0.461.06 ± 0.682.1190.076
LDL-C (mmol/L)2.41 ± 0.872.52 ± 0.932.45 ± 0.932.45 ± 0.892.52 ± 0.981.9150.105
ApoA1 (mmol/L)1.17 ± 0.271.15 ± 0.311.17 ± 0.311.16 ± 0.311.16 ± 0.310.3610.836
ApoB (mmol/L)0.83 ± 0.290.86 ± 0.380.85 ± 0.420.85 ± 0.420.85 ± 0.310.4970.738
Lp(a) (mmol/L)213.26 ± 170.24226.54 ± 192.78220.48 ± 174.53215.14 ± 180.06227.58 ± 184.830.9280.446
New generation stent, (%)599 (93.9)533 (94.2)811 (93.4)1030 (93.7)790 (94.6)1.1980.878
CTO, (%)113 (17.7)107 (18.9)197 (22.7)301 (27.4)204 (24.4)28.384<0.001
LM, (%)40 (6.3)39 (6.9)46 (5.3)79 (7.2)47 (5.6)3.9260.416
ML, (%)364 (57.1)349 (61.7)542 (62.4)735 (66.9)526 (63.0)17.2220.002
CCB, (%)71 (11.2)54 (9.6)110 (12.7)118 (10.8)86 (10.3)4.2030.379
β-Blockers, (%)246 (38.7)224 (39.8)348 (40.2)478 (43.7)310 (37.3)9.1620.057
ARB or ACEI, (%)133 (20.9)134 (23.8)194 (22.4)260 (23.8)178 (21.4)3.1260.537
Clopidogrel, (%)174 (27.4)174 (31.1)287 (33.3)334 (30.6)213 (25.7)14.2020.007
Aspirin, (%)445 (70.1)403 (71.8)573 (66.2)723 (66.2)512 (61.7)19.5360.001
Statins, (%)338 (53.3)320 (57.2)466 (54.2)596 (54.7)431 (51.9)4.2310.376
LVEDD (mm)49.98 ± 6.0650.12 ± 5.6749.73 ± 5.5950.10 ± 5.5349.96 ± 5.090.5900.670
LVEF (%)60.88 ± 7.2660.97 ± 7.2361.48 ± 6.9261.03 ± 7.2160.99 ± 6.960.8010.524

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; TG, triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; Lp(a), lipoprotein a; CTO, chronic total occlusion lesions; LM, left main lesions; ML, multivessel lesions; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.